Visceral obesity on chronic constipation, inflammation, immune function and cognitive function in patients with inflammatory bowel disease

Abstract Objective: Obesity has gained attention among patients with inflammatory bowel disease (IBD). The impact of visceral obesity on chronic constipation, inflammation, immune function and cognition after diagnosis of IBD is still unknown.Methods: This is a cross-sectional study of 140 IBD patients. Patients’ visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were measured by abdominal computerized tomography (CT) scans and were grouped according to visceral obesity. Baseline variables, chronic constipation status, inflammation status and immune function were compared. The implications of visceral obesity on cognitive function were evaluated using Mini-Mental State Examination (MMSE).Results: The prevalence of visceral obesity was 51% (37 out of 72) for CD patients and 26% for UC patients (18 out of 68 patients). CD patients with visceral obesity has higher incidence of chronic constipation (81% vs. 57%, P = 0.028), higher IL-6 levels (15.28 pg/ml vs. 9.429 pg/ml, P = 0.0073) and lower CD4+ T cells (32.7% vs. 44.0%, P < 0.001). For UC patients, patients with visceral obesity have the tendency of higher IL-6 levels (7.2 vs. 6.0 pg/ml, P = 0.053). VAT/SAT ratio is associated with BMI (r = 0.652, P < 0.001).Conclusions: IBD patients had high risks of visceral obesity. CD Patients with visceral obesity had higher prevalence of chronic constipation, higher inflammation levels, decreased immune function.

Download Full-text

Impact of Visceral Obesity on Chronic Obstipation, Inflammation, Immune Function and Cognitive Function Among Patients with Inflammatory Bowel Disease

10.21203/rs.3.rs-37390/v1 ◽

2020 ◽

Author(s):

Yemin Wan ◽

Dan Zhang ◽

Yunzhi Qian ◽

Shuchen Chang ◽

Haihua Qian

Keyword(s):

Inflammatory Bowel Disease ◽

Adipose Tissue ◽

Cognitive Function ◽

Immune Function ◽

Bowel Disease ◽

Visceral Obesity ◽

Cross Sectional Study ◽

Cross Sectional ◽

Inflammatory Bowel ◽

The Impact

Abstract Background: Obesity has gained attention among patients with inflammatory bowel disease (IBD). The impact of visceral obesity on chronic obstipation, inflammation, immune function and cognition after diagnosis of IBD is still unknown.Methods: This is a cross-sectional study of 140 IBD patients. Patients’ visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) were measured by abdominal computerized tomography (CT) scans and were grouped according to visceral obesity. Baseline variables, chronic obstipation status, inflammation status and immune function were compared. The implications of visceral obesity on cognitive function were evaluated using Mini-Mental State Examination (MMSE).Results: The prevalence of visceral obesity was 51% (37 out of 72) for CD patients and 26% for UC patients (18 out of 68 patients). CD patients with visceral obesity has higher incidence of chronic obstipation (81% vs. 57%, P = 0.028), higher IL-6 levels (9.3 vs. 6.0 pg/ml, P = 0.045) and lower CD4+ T cells (32.7% vs. 44.0%, P = 0.034). For UC patients, patients with visceral obesity have the tendency of higher IL-6 levels (7.2 vs. 6.0 pg/ml, P = 0.053).Conclusion: IBD patients had high risks of visceral obesity. Patients with visceral obesity had higher prevalence of chronic obstipation, higher inflammation levels, decreased immune function.

Download Full-text

Lactobacillus Reuteri DSM 17938 (Limosilactobacillus reuteri) in Diarrhea and Constipation: Two Sides of the Same Coin?

Medicina ◽

10.3390/medicina57070643 ◽

2021 ◽

Vol 57 (7) ◽

pp. 643

Author(s):

Angela Saviano ◽

Mattia Brigida ◽

Alessio Migneco ◽

Gayani Gunawardena ◽

Christian Zanza ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Emergency Department ◽

Abdominal Pain ◽

Human Health ◽

Bowel Disease ◽

Chronic Constipation ◽

Lactobacillus Reuteri ◽

Current Knowledge ◽

Gastrointestinal Symptoms ◽

Inflammatory Bowel

Background and Objectives: Lactobacillus reuteri DSM 17938 (L. reuteri) is a probiotic that can colonize different human body sites, including primarily the gastrointestinal tract, but also the urinary tract, the skin, and breast milk. Literature data showed that the administration of L. reuteri can be beneficial to human health. The aim of this review was to summarize current knowledge on the role of L. reuteri in the management of gastrointestinal symptoms, abdominal pain, diarrhea and constipation, both in adults and children, which are frequent reasons for admission to the emergency department (ED), in order to promote the best selection of probiotic type in the treatment of these uncomfortable and common symptoms. Materials and Methods: We searched articles on PubMed® from January 2011 to January 2021. Results: Numerous clinical studies suggested that L. reuteri may be helpful in modulating gut microbiota, eliminating infections, and attenuating the gastrointestinal symptoms of enteric colitis, antibiotic-associated diarrhea (also related to the treatment of Helicobacter pylori (HP) infection), irritable bowel syndrome, inflammatory bowel disease, and chronic constipation. In both children and in adults, L. reuteri shortens the duration of acute infectious diarrhea and improves abdominal pain in patients with colitis or inflammatory bowel disease. It can ameliorate dyspepsia and symptoms of gastritis in patients with HP infection. Moreover, it improves gut motility and chronic constipation. Conclusion: Currently, probiotics are widely used to prevent and treat numerous gastrointestinal disorders. In our opinion, L. reuteri meets all the requirements to be considered a safe, well-tolerated, and efficacious probiotic that is able to contribute to the beneficial effects on gut-human health, preventing and treating many gastrointestinal symptoms, and speeding up the recovery and discharge of patients accessing the emergency department.

Download Full-text